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Background: Improving the quality of care for people with dementia and their carers has become a national
priority in many countries. Cognitive Stimulation Therapy (CST) groups can be beneficial in improving cognition
and quality of life for people with dementia. The aim of the current study is to develop and evaluate a home-based
individual Cognitive Stimulation Therapy (iCST) programme for people with dementia which can be delivered by
their family carer.
Methods: This multi-centre, pragmatic randomised controlled trial (RCT) will compare the effectiveness and
cost-effectiveness of iCST for people with dementia with a treatment as usual control group. The intervention
consists of iCST sessions delivered by a carer for 30 minutes, 3 times a week over 25 weeks.
For people with dementia the primary outcome measures are cognition assessed by the ADAS-Cog, and quality of
life assessed by QoL-AD. For carers, quality of life using the SF-12 is the primary outcome measure. Using a 5%
significance level, comparison of 306 participants will yield 80% power to detect an effect size of 0.35 for cognition
as measured by the ADAS-Cog, and quality of life as measured by the QoL-AD. Quality of life for the carer will be
measured using the SF-12. The trial will include a cost-effectiveness analysis from a public sector perspective.
Discussion: The UK Department of Health has recently stressed that improving access to psychological therapies is
a national priority, but many people with dementia are unable to access psychological interventions. The
development of a home-based individual version of CST will provide an easy to use, widely available therapy
package that will be evaluated for effectiveness and cost-effectiveness in a multi centre RCT.Background
Caring for people with dementia has an enormous im-
pact on health and social care services and on family
carers [1]. The cost of dementia in the UK is over £17
billion a year [2]. With the number of people living with
dementia expected to double in the next thirty years, im-
proving the quality of care for people with dementia and
their carers has become a national priority [1]. In the
UK there is growing recognition that psychological ther-
apies for dementia should be more widely available. In-
deed the National Service Framework for Older People
emphasises the use of non-pharmacological management
strategies, such as mental stimulation for dementia, and* Correspondence: lauren.yates@ucl.ac.uk
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reproduction in any medium, provided the orthe UK Department of Health has identified improving
access to psychological therapies as a priority [3].
Cognitive Stimulation Therapy (CST) is an evidence-
based approach for people with dementia developed fol-
lowing Cochrane reviews of several psychosocial therapies
for dementia, primarily reality orientation (RO) [4]. RO
involves the presentation and repetition of orientation in-
formation, such as the date, day and weather [5]. This
may take place intensively throughout the day, or in regu-
lar structured group meetings. Benefits of RO noted in the
Cochrane review [4] included improved behaviour and
cognition. In addition the need for a more detailed and
ongoing programme of orientation activities and large
scale multi-centre trials to evaluate this approach was
identified. Spector et al. found that participating in CST
improved quality of life and cognition for people withtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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anti-dementia drug treatments [6]. CST is currently the
only non-pharmacological therapy recommended by the
National Institute for Health and Clinical Excellence
(NICE) guidelines [7] to improve cognition in people with
mild to moderate dementia. A pilot study of an extended
programme of maintenance CST found a significant im-
provement in cognitive function for those receiving main-
tenance CST, suggesting that benefits could be maintained
by weekly sessions for at least 6 months [8]. Olazaranet al.
also found that CST groups had long-term cognitive bene-
fits for people with dementia [9]. The Maintenance CST
programme (comprising 14 CST sessions over 7 weeks
plus an additional 24 weekly maintenance CST sessions)
and accompanying manual have now been further devel-
oped as part of the SHIELD study [10] and evaluated in a
randomised controlled trial (RCT). The results of the
Maintenance CST trial are expected soon.
The use of group CST is growing rapidly in the UK
and internationally, yet many people with dementia may
be unable or unwilling to participate in group CST. This
could be because they do not want to go out, or because
they have restricted mobility or health issues that pre-
vent them from getting out; they may choose not to par-
ticipate in group-based activities, or groups may not be
running in their local area. To assess the acceptability of
an individualised CST programme we surveyed care staff
attending CST training sessions and carers from the
charity For Dementia, and we spoke to carers and people
with dementia. There was a consensus from people with
dementia and family carers that individualised CST
should be a high priority because it was likely to be very
useful. Comments included 'sounds terrific', 'could bring
the carer and person with dementia closer together',
'good for people who won't go out', and 'definitely
needed as a useful alternative to medication'. Taken to-
gether the evidence suggests that a large-scale trial of
iCST for dementia in the UK is feasible, likely to be
effective and should be a high priority for research.
Few studies have focused on the use of cognitive
stimulation programmes in the home environment. In a
pilot study, Moniz-Cook et al. [11] found that a home-
based memory management programme involving the
family carer led to improvements in memory in the per-
son with dementia, improvements in carer wellbeing,
and a reduction in care home admissions at 18 months
follow-up. Similar benefits in cognition in people with
dementia and carer wellbeing have been reported in
studies by Quayhagenet al. [12] and Quayhagen and
Quayhagen [13]. Onder et al. [14] carried out a study of
patients with Alzheimer’s disease (AD) taking cholin-
esterase inhibitors. The intervention consisted of a stan-
dardised programme of RO delivered by the family carer
in the home for 30 minutes, three times a week over 25weeks. Alongside training, carers were given a manual,
specific schedules for each session, and guidance on how
to deliver the sessions. The experimental group receiving
the intervention improved relative to the control group
on both the Mini Mental State Examination (MMSE)
and the Alzheimer’s Disease Assessment Scale – Cognitive
subscale (ADAS-Cog).
The primary aim of the proposed trial is to investigate
whether individual home-based CST benefits cognition
and quality of life in people with dementia and improves
carer well-being. Based on previous research findings,
we hypothesize that people with dementia receiving
iCST will show improvements in cognition and quality
of life. A secondary aim of the trial is to explore the
costs of those receiving iCST compared to a control
group, and to investigate whether iCST is cost-effective.
Methods
Design
The design is a multi-centre, single blind, randomized,
two-treatment arm (iCST over 25 weeks vs. treatment as
usual, or TAU), controlled clinical trial (Figure 1). After
recruitment and baseline assessments, pairs of people
with dementia and their carer are randomly allocated
into either the treatment group (receiving three 30-
minute weekly sessions of iCST delivered by the carer
for 25 weeks) or control group (receiving treatment as
usual for 25 weeks). Primary and secondary measures
are completed at baseline (T0) before the iCST
programme, first follow-up at 13 weeks after baseline
(T1) and second follow-up and primary endpoint at 26
weeks after baseline (T2).
Sample size
Cognition (ADAS-Cog) will be the primary outcome
measure. The group CST study by Spector et al. [5] had
an effect size (standardised mean difference, or SMD) of
0.32.The Spector et al. Cochrane Review of RO [4] found
an SMD of 0.58. The Maintenance group CST study [8]
found an SMD of 0.68 compared to TAU. A recent
Cochrane Review of cognitive stimulation found an SMD
of 0.37 [15]. Taking a conservative estimate, SMD relative
to TAU for iCST is estimated to be at least 0.35. In order
to detect an SMD for iCST of 0.35 on the ADAS-Cog
with 80% power at a 0.05 (two-sided) significance level,
and assuming 15% attrition, a sample size of 306 people
with dementia will be required. Experience in previous
trials including the CST trial, the needs in care homes
trial [16], and the activities in care homes trial [17], indi-
cates a 12 to 15% loss to follow-up (7 to 10% excluding
deaths) is likely. To safeguard loss to follow-up, standard
procedures to maximize the follow-up sample will be ap-
plied. These will include regular contact with carers via
telephone, letters (for example, reminders for assessment
Recruit N= 306 participants across 4 centres 
screened by inclusion criteria: dementia, living 
in the community, MMSE 10+, some ability to 
communicate, family carer available.
Baseline data collection
Remote randomisation
N= 153 allocated to iCST 
intervention group
N= 153 allocated to treatment 
as usual group
Outcome measures at 13 
weeks
Follow up at 26 weeks 
N= 260
iCST Training and start of 
iCST programme
Outcome measures at 13 
weeks
iCST programme complete at 
25weeks
Figure 1 Flow of participants through the iCST randomised
controlled trial.
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carer.
Participants
Recruitment to this trial will take place in a variety of
community settings including community mental health
teams for older people (Chats), memory clinics, out-
patient clinics, day centres and voluntary sector organisa-
tions such as Age Concern and the Alzheimer’s Society.
Some participants in both the intervention and TAU
groups will be taking anticholinesterase inhibitors; in
these cases participants will continue taking them
throughout the study. Participants will be screened for
eligibility using the Spector et al. [4] standardised criteria
for psychological treatment of people with dementia. Par-
ticipants must meet the Diagnostic and Statistical Man-
ual of Mental Disorders (DSM)-IV criteria for dementia,
have dementia of mild to moderate severity (MMSE≥10), have some ability to communicate and understand,
and be able to see and hear well enough to participate in
activities. In addition, they must have a carer who will be
available to deliver the intervention, live in the commu-
nity, and have no major illness which could affect partici-
pation. Participants may only enter the study after giving
informed consent in accordance with the provisions of
the Mental Capacity Act 2005 [18].
Randomisation
Randomisation will occur after screening and baseline
assessments. The allocation ratio for randomisation is
1:1, into either the intervention group or control group
(TAU). Participants will be stratified by centre (London,
Bangor, Hull or Manchester) and whether they are tak-
ing anticholinesterase inhibitors, to ensure even distribu-
tion of the sample between the treatment and control
groups. Registered participants will be randomised by
the web-based randomisation service managed by North
Wales Organisation for Randomised Trials in Health
(NWORTH), an accredited UK Clinical Trials Unit. The
randomisation algorithm is a dynamic adaptive method
that ensures balance overall, within each stratification
variable and within each stratum. This allows sequential
randomisation of participants, minimising selection bias
while maintaining an acceptable level of balance [19].
Although participants cannot be blinded to their treat-
ment allocation, researchers carrying out follow-up
assessments will be blinded to the treatment condition.
Our experience shared by similar projects is that partici-
pants may occasionally inadvertently reveal their alloca-
tion to researchers. In order to reduce this effect,
participants will be given explicit reminders before the
experimental visit and self-reported measures will be
used wherever feasible. Assessors will record their im-
pression of which arm of the trial each participant
belongs to, and their confidence in that prediction. This
will enable us to conduct a retrospective estimation of
the integrity of blinding, to test whether inadvertent loss
of blinding leads to bias, and to adjust for any bias
detected.
Intervention
The iCST programme is based on a modified CST man-
ual, the recent Cochrane review of cognitive stimulation
[15], Onder’s programme [14] and consultation with
carers and people with dementia. iCST will be delivered
by a carer in regular contact with the person with de-
mentia for 30 minutes, three times a week over 25
weeks. The iCST programme comprises 75 iCST ses-
sions consisting of structured cognitive stimulation
through themed activities (for example, number games,
associated words) (Table 1) tailored to the ability, inter-
ests and needs of the individual. Carers will receive the
Table 1 Individual cognitive stimulation therapy (iCST)
themes
iCST Session theme Session number
My life 1, 2, 45, 46
Current affairs 3, 4, 57, 58
Food 5, 6, 55, 56
Being creative 7, 8, 63, 64
Number games 9, 10, 71, 72
Quiz games 11, 12, 75
Sounds 13, 14, 51, 52
Physical games 15, 16, 49, 50
Categorizing objects 17, 18, 65, 66
Household treasures 19, 20
Useful tips 21, 22, 47, 48
Thinking cards 23, 24
Visual clips discussion 25, 26
Art discussion 27, 28, 43, 44
Faces/scenes 29, 30, 59, 60
Word games 31, 32, 41, 42, 73, 74
Slogans 33, 34
Associated words/discussion 35, 36, 61, 62
Orientation 37, 38, 67, 68
Using money 39, 40, 69, 70
Childhood 53, 54
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use during the programme. The Manual provides guid-
ance on how to run the sessions, the key principles of
iCST and ideas for activities for each session. The Activ-
ity Workbook contains paper-based resources for activ-
ities suggested in the manual. Carers will also be
provided with the iCST kit, which will include additional
resources such as a deck of cards, set of dominoes, mag-
nifying card, sound activity compact discs (CDs), set of
boules, and world and UK maps. A first draft of the
iCST Manual, Activity Workbook and iCST kit will be
developed by the research team, and presented to people
with dementia and carers in interviews and focus groups
(adhering to Medical Research Council (MRC) guidance
[20]). The purpose of consultation with service users is
to ensure that the Manual and Activity Workbook are
easy to use, describe meaningful activities, are appropri-
ately tailored to people with mild and moderate demen-
tia, and that the iCST kit contains suitable items. The
iCST package will be further evaluated using the Delphi
process of consensus methodology, in line with guide-
lines for consensus methods in medical and health ser-
vices research [21]. A feasibility study with a sample of
20 people with dementia and their carers will be carried
out prior to the main RCT. A final draft of the iCSTpackage incorporating findings from the feasibility study
will be produced for use in the full trial.
Treatment adherence, carer training, and support
Previous research suggests that in order to investigate
treatment process variables, and to ensure that psycho-
social interventions can be replicated, it is necessary to
have precise descriptions of treatment components, and
to ensure that the treatment delivered was indeed the
treatment intended. We will follow previous studies [22]
applying the treatment integrity model, developed and
expanded by Lichstein, Riedel and Grieve [23].Carers
will receive standardised training either in their homes
or in a group setting, according to which is most con-
venient for the carer. The training that researchers will
provide to carers will focus on how to use the iCST
Manual and Activity Workbook, implementing the key
principles of CST and problem solving strategies. In the
training session the researcher will show clips of good
practice in CST from the Making a Difference 2 training
digital video disc (DVD). The DVD was developed as
part of the Maintenance CST trial [10]. If the training
session is home-based, the carer will be invited to deliver
the first session with support from the researcher, who
will provide assistance and feedback. Carers will receive
the iCST Manual, Activity Workbook and kit as part of
a training and set-up visit. Researchers will be guided by
a standardised treatment protocol detailing training pro-
cedures and support provided. During the trial carers
will receive up to ten hours of support over six months,
including telephone support (initially weekly) and two
visits from the unblinded researcher. In the event that
the family carer is unable to continue delivering iCST,
another appropriate carer can be substituted.
Usual care
The control group will receive TAU, which may vary be-
tween and within centres and change over time, there-
fore the study will evaluate the additional effects of
iCST. In terms of treatment we would expect most
people with mild to moderate AD will either be on, or
have been considered for, cholinesterase inhibitor medi-
cation. The Client Service Receipt Inventory (CSRI) will
enable us to accurately record use of drugs and services
across the two groups and any changes that occur. In
general, the services offered to this group will also be
available to those in the active treatment group, so we
will be examining the additional effects of iCST.
Resource use
The CSRI [24] will allow us to record the utilisation of ser-
vices and the interventions received during the study, and
the support provided by carers, as well as the use of cho-
linesterase inhibitors and other psychiatric medications
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be collected on the inputs required to deliver the
intervention.
Ethical approval
Ethical approval was obtained through the Multi-centre
Research Ethics Committee (ref no.10/H0701/71), and
the study is registered as a clinical trial (ISRCTN
65945963). There appear to be no documented harmful
side effects from participating in CST groups, and no
serious adverse reactions were apparent in the CST
study [5]. Prospective participants will be fully informed
of the potential risks and benefits of the project. A
reporting procedure will be in place to ensure that any
serious adverse events are reported to the Chief Investi-
gator. Participants will be in the mild to moderate stages
of dementia, and would therefore generally be expected
to be competent to give informed consent for participa-
tion, provided that appropriate care is taken to explain
the research. Where the participant’s level of impairment
increases, so that he/she is no longer able to provide
informed consent, the provisions of the Mental Capacity
Act [18] will be followed, with the family caregiver as a
consultee.
Outcome measures
Primary outcome measures for the person with dementia
Cognition will be measured using the ADAS-Cog [25],
which consists of 11 tasks assessing disturbances of
memory, language, praxis, attention and other cognitive
abilities, referred to as the core symptoms of AD, with
good reliability and validity [26].Quality of life will be
measured using the Quality of Life Alzheimer’s disease
Scale (QoL-AD) [27] which consists of 13 domains of
quality of life. The measure is recommended by the
European consensus on outcome measures for psycho-
social interventions in dementia [28].
Secondary outcome measures for the person with dementia
Quality of life will also be measured with the Dementia
Quality of Life (DEMQOL) scale [29]. The scale uses
self-rated reports of quality of life across five domains
administered to the person with dementia by a trained
interviewer. It has high internal consistency, acceptable
inter-rater reliability and good concurrent validity, with
moderate associations with the QoL-AD [30]. It is
included as a quality of life scale and a utility measure
since an algorithm is now available to convert the DEM-
QOL and DEMQOL-proxy into utility scores [31].Be-
haviour will be assessed using the Neuropsychiatric
Inventory (NPI) [32]. The NPI measures 10 behavioural
disturbances occurring in dementia patients. It is
reported to be both valid and reliable [33]. Functional
ability of the person with dementia will be assessedusing the Bristol Activities of Daily Living Scale
(BADLS) [34], which is a carer-rated instrument asses-
sing items rated as important by carers in 20 daily-living
abilities. The measure shows sensitivity to change in
people with AD taking anticholinesterase medication,
and is associated with changes in the ADAS-Cog [35].
Depressive symptoms will be measured by the Geriatric
Depression Scale (GDS-15) [36], comprising 15 easy-
to-use items. The GDS-15, although principally a self-
rating scale, may be used as an observer-administered
scale, with acceptable sensitivity and specificity in people
with mild to moderate dementia [37].Quality of the
carer-patient relationship (QCPR) [38] will be assessed
by both the carer and the person with dementia. The
QCPR is a measure of relationship quality, comprising
14 items designed to assess warmth, levels of conflict
and criticism in the caregiving relationship. Previous
studies have shown that the QCPR has good internal
consistency and concurrent validity [38].
Primary outcome measures for the carer
Health-related quality of life will be measured using the
Short Form-12 Health Survey (SF-12) [39]. The SF-12 is
a comprehensive, psychometrically sound, and efficient
measure of health which includes eight concepts com-
monly represented in health surveys: physical function-
ing, role functioning, physical pain, general health,
vitality, social functioning, emotional and mental health.
Secondary outcome measures for the carer
Anxiety and depression will be assessed using the Hos-
pital Anxiety and Depression Scale (HADS) [40], a
widely used measure of self-reporting consisting of 14
questions, validated in several age groups, which identi-
fies caseness for clinically significant depression and
anxiety [41].Self-reported health related quality of life
will be measured using the EQ-5D [42]. The EQ-5D is a
self completed measure yielding a simple descriptive
profile and a single index value for health status. It has
been used in a wide range of study populations (Pickard
et al., 2007 [43]; Dyer et al., 2010 [44]). Resilience in
carers will be measured with the Resilience Scale (RS-
14) developed by Wagnild and Young [45]. In the
shorter version of this scale participants are asked to re-
spond to each item by either agreeing or disagreeing
with each statement, with higher scores indicating stron-
ger resilience. Previous studies have shown that the
measure demonstrates high internal consistency and
construct validity [46].
Economic measures
Care and support levels will be assessed using the CSRI
[24], adapted for this study and used extensively in stud-
ies of mental health and dementia. The CSRI gathers
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services received, as well as details of unpaid support
from carers, and wider carer economic impacts. A form
for monitoring treatment adherence will be devised for
this study and will include questions on the amount of
time required from professionals and carers to support
the delivery of the training package. Costs of care and
support can be estimated from these service-use data by
applying relevant, nationally generalisable unit costs,
drawing on the National Health Service (NHS) reference
costs [47] and the annual Personal Social Services Re-
search Unit (PSSRU) volume [48]. The costs of deliver-
ing the training package (excluding costs of the initial
development and testing of the package) will be calcu-
lated from the perspective of commissioners (NHS, local
government) and also in terms of costs to carers of their
time. Costs will be reported in aggregated and disaggre-
gated form (NHS overall, local government, society as a
whole) to show total programme cost, cost per partici-
pant (person with dementia), and cost per participant-
carer pair. Cost effectiveness will be computed in a
number of different ways as the difference in costs be-
tween the iCST and control group over the trial period,
divided by the difference in outcomes (cognition, quality
of life, or QALYS). See the Economic evaluation section
below for details.
Analysis
An intention-to-treat analysis will be carried out, in that
all available data will be included. A method of multiple
imputation using a linear regression model will be used
where needed for imputing missing data. The sample
size calculations are based on the numbers estimated to
be available at the study endpoint, 6 months after ran-
domisation. Analysis of covariance will be used to adjust
for baseline differences that may influence outcome vari-
ables. Variables to be considered in the model will in-
clude, among others, gender and age. Analyses will
consider the evaluation 6 months after randomisation as
the primary endpoint in evaluating the effectiveness of
iCST. Further model definition will be provided in the
statistical analysis plan.
Economic evaluation
The main economic evaluation will be a cost-
effectiveness analysis (CEA),first from a health and social
care perspective, and second, from a societal perspective.
Service-use data, and information on unpaid carer sup-
port will be collected using an adapted CSRI, and then
converted into estimates of costs by applying nationally
generalisable unit cost data.
Carer inputs will be costed in two ways, using either a
replacement cost assumption or an opportunity cost as-
sumption (Koopmanschap, 2008 [49]; Pritchard, 2000[50]). The primary CEA will measure effectiveness using
the ADAS-Cog; further analyses will look at other out-
comes, particularly quality of life as measured by the
QoL-AD and QALYs generated from the DEMQOL and
DEMQOL-proxy by applying societal weights [31]. The
use of QALYs will allow bodies such as NICE to make
recommendations about the use of health and social care
resources so as to achieve the greatest impact from given
budgets; cost-per-QALY calculations are increasingly
used in health systems in pursuit of greater allocative ef-
ficiency (Smith and Richardson, 2005 [51]; Rawlins and
Culyer, 2005 [52]). Each such CEA will be conducted
from a health and social care perspective, and then from
a societal perspective.
Cost-effectiveness acceptability curves will be plotted,
generated from the net benefit approach and using boot-
strap regression for a range of values of willingness to
pay for incremental primary outcome measure changes
and QALY gains. CEACs are widely employed as a way
to quantify and graphically represent uncertainty in eco-
nomic evaluation studies of health care technologies
[53]. The economic evaluation will be fully integrated
into the main outcome evaluations. Sensitivity analyses
will be carried out to determine whether changes in the
values of the main parameter estimates affect the results
of the analyses.
Discussion
This is an innovative RCT that evaluates the effective-
ness and cost-effectiveness of individual CST for people
with dementia and their carers. The development of
carer-led therapies could ease pressure on local services,
which are in great demand but often severely limited. In
2009, the UK National Audit Office reported that CST
was available in 29% of CMHTs for older people [54]
and a home-based version of CST, could help people
with dementia having limited access to CMHT services.
By placing emphasis on working with the person with
dementia and family carer together, the study meets the
current demand for relationship-centered care and will
provide the opportunity to explore the dynamics of
carer-led therapies compared to professional-led therap-
ies. We anticipate that actively involving carers in the
delivery of a therapy package will be empowering, and
will also have a positive impact on their well-being.
The NICE-Social Care Institute for Excellence (SCIE)
guidelines [7] on the management of dementia offer few
evidence-based recommendations on psychosocial
approaches, due to a paucity of high quality RCTs. The
current RCT is the first study to assess the cost-
effectiveness of an individualised carer-led cognitive
intervention in dementia.
The potential benefits of iCST include improved well-
being for people with dementia and their carers, and
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care and delayed institutionalisation. iCST can also be
offered in combination with anti-dementia medication,
and also provides an option for those unsuitable for, or
unwilling to take medication. However, the success of
iCST will be heavily dependent on family carers being
motivated and able to invest time to adhere to the
programme. The number of commitments (for example,
hospital appointments) and responsibilities (for example,
household upkeep) carers have on an everyday basis,
and how well they are coping with caring for their rela-
tive with dementia may have an impact on adherence to
the programme. In addition, carer’s confidence in their
ability to adopt a therapeutic role delivering iCST ses-
sions may also affect the success of the programme, as
some may consider this to be a role best occupied by
healthcare professionals and day centre staff. Providing a
high quality interactive training package and adequate
support for carers will be key to avoiding or minimising
the impact of these potential issues.
A longer term follow up would be beneficial to exam-
ine rates of institutionalisation and cost of care in the
months or years following completion of the iCST
programme, to determine whether iCST plays a role in
delaying institutionalisation and reducing the cost of
care beyond the duration of taking part in the sessions.
The trial results will contribute to future practice guide-
lines and, if successful, the iCST programme could be
widely used across the UK and internationally, and be-
come the gold standard for individual cognitive
stimulation-based interventions in dementia.Trial status
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